Floatz logo

TACROLIMUS

Philadelphia Positive Acute Lymphoblastic Leukemia

CANDONI ANNASmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Philadelphia Positive Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
PREDNISONE TABLETS
SWOG Cancer Research Network
Phase 3BB
Ruxolitinib
University Health Network, Toronto
Phase 1/2CCC
Olverembatinib
Ascentage Pharma Group Inc.
Phase 1CC
lp-118
Wake Forest University Health Sciences
Phase 1CC

View all 9 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →